Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

BioMimetic Therapeutics secures new patent in orthopedic product line

BioMimetic Therapeutics has received the Canadian Intellectual Property Office (CIPO) patent application No 2,583,823 titled 'Platelet Derived Growth Factor (PDGF) Compositions and Methods of Use Thereof'.

The new patent will remain in force until October 2025, during which time it will prohibit the marketing of similar or generic versions of the BioMimetic’s Augment orthopedic product line and certain other rhPDGF-BB product formulations.

The Canadian patent will contain 200 claims covering compositions and methods of using recombinant platelet derived growth factor (rhPDGF-BB) combined with various matrix materials having defined characteristics.

The patent will provide protection in Canada for the BioMimetic‘s recombinant protein-device combination product candidates, including Augment Bone Graft and Augment Injectable Bone Graft.

Augment was licensed by Health Canada for use in foot and ankle fusion indications in November 2009 and is currently being marketed through an indirect sales force.

BioMimetic Therapeutics president and CEO Samuel Lynch said they are pleased with their first notice of patent allowance covering Augment, Augment Injectable and many related formulations of rhPDGF-BB platform technology in Canada.

"We continue to aggressively pursue intellectual property coverage worldwide. In addition to the allowed claims in Canada, we have corresponding coverage and protection for our technology in many other major international markets, and in the US," Lynch said.

"The advancement of our patent portfolio comes at an optimal time, as we recently completed enrollment in a pivotal trial in Canada to evaluate Augment Injectable as a replacement for autograft and are in active discussions with Health Canada regarding the submission of the DLA required for product approval."